A Decade-Long Puzzle Solved: How a Rare Gene Mutation Links Autism to Parkinson's

HOUSTON, TX – For years, Jennifer and Dr. Peter Johnson harbored a gnawing suspicion: Owen’s autism diagnosis, received at age three, didn’t fully encompass the complex array of symptoms their son experienced. His initial developmental delays in speech and struggles connecting with peers at his Houston preschool were consistent with autism spectrum disorder, and early therapy brought some relief. Yet, as Owen grew, a perplexing divergence emerged. The gap between him and his twin sister, Alice, widened, and his once-vibrant personality began to recede. This intuitive feeling, born from parental observation and a father’s neurological expertise, would eventually lead to a groundbreaking discovery connecting a rare gene mutation to both neurodevelopmental disorders and Parkinson’s disease.

The journey from a vague sense of unease to a precise genetic diagnosis highlights the relentless pursuit of answers by families and the transformative power of cutting-edge scientific research. Owen’s story is a powerful testament to the evolving understanding of neurodevelopmental conditions, where breakthroughs in one field can unexpectedly illuminate another, offering hope for targeted therapies where none existed before.

Table of Contents

Unlocking the Mystery: A Converging Scientific Breakthrough

In a significant advancement for both neurodevelopmental and neurodegenerative research, scientists at the Jan and Dan Duncan Neurological Research Institute (NRI) at Texas Children’s Hospital have identified a rare genetic mutation in the ITSN1 gene as a causative factor for a spectrum of neurodevelopmental disorders, including autism, and a heightened risk for Parkinson’s disease later in life. This discovery emerged serendipitously from research initially focused on Parkinson’s, profoundly impacting families like the Johnsons who had long sought a deeper explanation for their children’s complex symptoms.

Owen Johnson, now ten years old, was diagnosed with autism at three. His parents observed him becoming increasingly withdrawn and struggling with mood and concentration, symptoms that didn’t entirely fit the typical autism narrative. Their search for answers led to genetic testing in 2021, which initially yielded no conclusive information. Concurrently, across Houston, Dr. Ryan Dhindsa’s lab at the Duncan NRI was investigating genetic risk factors for Parkinson’s disease. Utilizing advanced artificial intelligence to analyze DNA from hundreds of thousands of patients, Dhindsa’s team identified a suspicious mutation in the ITSN1 gene. Further research soon revealed that this same mutation was not only linked to Parkinson’s but also to neurodevelopmental disorders, providing a crucial missing piece for families like the Johnsons. This convergence of clinical observation and cutting-edge genetic analysis has opened a new frontier in understanding and potentially treating these challenging conditions.

Owen’s Journey: The Quest for Deeper Understanding

Owen’s early childhood gave little indication of the complex challenges that lay ahead. While he began speaking later than typical and sometimes fixated on specific objects or colors, his parents initially attributed these traits to the unique unfolding of a toddler’s personality. Even his preschool teachers expressed surprise when the Johnsons shared his autism diagnosis, suggesting that Owen’s presentation was not overtly severe.

However, as Owen transitioned from his early toddler years, a noticeable shift occurred. "He had always been a very happy child in his early toddler years, and then he would just get so withdrawn," recalled his mother, Jennifer Johnson, her voice tinged with concern. "I was really concerned." The lively, energetic child who loved playing and singing with his three sisters – older twins Audrey and Evelyn, and his own twin, Alice – began to struggle. His ability to focus in school waned, and he stopped participating in beloved family traditions, such as singing a special song with his siblings every Mother’s Day.

Despite Owen’s ongoing therapy and medication adjustments recommended by his pediatrician, the Johnsons couldn’t shake the feeling that something more profound was at play. As a neurologist himself, Dr. Peter Johnson brought a professional perspective to their concerns, reinforcing their intuition that Owen’s symptoms transcended a typical autism diagnosis. "It’s a helpless feeling," Dr. Johnson articulated, reflecting on the frustration of hitting diagnostic dead ends. "If you don’t have an answer, then what can you do?" Their initial genetic testing in 2021, which offered no new insights, only amplified this sense of helplessness, leaving them adrift in a sea of uncertainty.

The Serendipitous Discovery of ITSN1: A Parallel Path

While the Johnsons grappled with unanswered questions, a crucial piece of their puzzle was being forged miles away in Dr. Ryan Dhindsa’s laboratory at the Jan and Dan Duncan Neurological Research Institute, part of Texas Children’s Hospital. Dhindsa and his team were engaged in a large-scale research effort to pinpoint genetic risk factors for Parkinson’s disease, a neurodegenerative condition primarily affecting older adults.

The human genome, a sprawling instruction manual of over 3 billion base pairs of DNA, is incredibly complex. Every child is born with approximately 70 de novo or spontaneous genetic mutations—changes in DNA that are not inherited from either parent. While most of these mutations are benign, a small fraction can strike critical genes, leading to genetic disorders. "Sometimes we get unlucky, and that (mutation) hits a really important gene," Dhindsa explained, underscoring the delicate balance of genetic lottery.

To navigate this immense genetic landscape, Dhindsa’s lab employed sophisticated artificial intelligence algorithms to sequence and analyze DNA from roughly 800,000 patients. By meticulously comparing the genetic profiles of individuals with Parkinson’s to those without the disease, a consistent pattern emerged: a significant number of Parkinson’s patients harbored a specific mutation in a gene named ITSN1. This gene is responsible for producing a vital protein that facilitates communication between brain cells, a process fundamental to healthy neurological function. Over several years of rigorous testing, Dhindsa’s team validated their initial findings, determining that individuals carrying an ITSN1 variant are an astonishing 10 times more likely to develop Parkinson’s disease.

Crucially, as their understanding of ITSN1 deepened, the researchers made an unexpected observation. The ITSN1 variants were not only prevalent in Parkinson’s patients but also appeared with unusual frequency in a distinct cohort: children diagnosed with autism or other neurodevelopmental disorders. This cross-pollination of findings between seemingly disparate conditions laid the groundwork for a profound diagnostic shift.

The Obscure Answer: Connecting the Dots

The first tangible link for the Johnsons arrived in mid-2022, when Jennifer Johnson opened an email from the lab that had performed Owen’s initial genetic testing a year prior. The letter, a somewhat cryptic message, stated that the lab had recently become aware of new research indicating that ITSN1 variants were "likely pathogenic," implying a strong probability of causing neurodevelopmental disorders akin to autism. However, the letter offered no further context or information, leaving the Johnsons to piece together an incomplete puzzle.

Their subsequent attempts to find answers were met with frustration. Scouring the internet yielded little to no understandable information about ITSN1 or its implications for Owen’s future. His doctors and therapists, unfamiliar with this newly identified variant, could offer no guidance. "There was a little piece of the puzzle that was maybe filled in, but it just didn’t give a clear enough picture," Jennifer Johnson lamented, articulating the lingering uncertainty.

Undeterred, the Johnsons sought out specialized expertise. The following year, they took Owen to Texas Children’s Hospital to consult with Dr. Sarah Risen, a distinguished pediatric neurologist. Dr. Risen initiated further genetic testing, which unequivocally confirmed the presence of the ITSN1 variant in Owen. Armed with this new information, she began to adjust Owen’s medications, tailoring them to potentially address the specific neurological pathways implicated by the ITSN1 mutation.

The critical turning point arrived in early 2025. Dr. Risen informed Owen’s parents that a pioneering scientist at the Duncan NRI, Dr. Ryan Dhindsa, was actively studying the ITSN1 variant as part of his Parkinson’s research. Recognizing the profound implications for Owen, Dr. Risen swiftly arranged a meeting between the Johnson family and Dr. Dhindsa, finally bringing together the clinical mystery and the scientific discovery.

A Puzzling Diagnosis: The Enigmatic Nature of ITSN1-Related Syndrome

The ITSN1 variant is remarkably rare, affecting an estimated one in 5,000 people. This rarity, coupled with its perplexing clinical presentation, makes Dhindsa’s lab one of only a handful globally dedicated to its study. The variant’s enigmatic nature stems from its variable penetrance and expression. In approximately 60% of cases where a child inherits the variant from a parent, that parent appears to be clinically unaffected, raising questions about modifying genetic or environmental factors.

Furthermore, the manifestation of ITSN1-related syndrome presents a curious dichotomy. Children with the variant are typically first diagnosed with neurodevelopmental conditions such as autism and ADHD. Yet, most adults who carry ITSN1 variants and later develop Parkinson’s disease have no documented history of neurodevelopmental disorders during their childhood. This suggests a complex interplay of genetic expression, developmental windows, and potentially other factors that determine whether the variant manifests early in life as a developmental challenge or later as a neurodegenerative disease.

These mysteries are characteristic of the research conducted at the Duncan NRI, an institution specifically dedicated to investigating genes, like ITSN1, linked to rare pediatric brain disorders. Dr. Huda Zoghbi, a renowned neurogeneticist and the founding director of the Duncan NRI, emphasizes the fundamental role of genetics in understanding neurological health and disease. "Genes are a good entry point for understanding how the brain doesn’t function properly or why it’s vulnerable to degradation later in life," she states. This foundational knowledge is critical for scientists to identify preventative strategies, develop targeted medications, and craft effective therapies. "Once you know that," Dr. Zoghbi asserts, "We can then begin to say, ‘How do you reverse it?’"

Complex Genetic Research: Charting the Path Forward

The Johnsons met Dr. Dhindsa last year, shortly after he co-authored a pivotal study definitively linking ITSN1 variants to an elevated risk of Parkinson’s. They are now among approximately 20 families actively collaborating with Dhindsa’s lab, contributing invaluable insights to the burgeoning understanding of ITSN1-related syndrome.

A key component of this ongoing research is a natural history study. Dhindsa’s lab is meticulously tracking individuals with ITSN1 variants over many years, observing and documenting the progression of their symptoms. The clinical spectrum of ITSN1-related syndrome is broad and challenging, ranging from mild symptoms like ADHD or moderate learning disabilities to severe manifestations, including seizures or profound language regression, where some affected individuals gradually lose the ability to speak, even as late as their teenage years. This longitudinal data is crucial for understanding the full phenotypic range of the disorder and identifying potential prognostic markers.

Beyond observational studies, the Duncan NRI is employing advanced genetic research techniques to unravel the molecular mechanisms of ITSN1 variants. In a remarkable feat of cellular engineering, Dhindsa’s lab obtained a sample of Owen’s skin cells. Using sophisticated gene-editing technology, these somatic cells were "reprogrammed" into induced pluripotent stem cells. These stem cells were then differentiated into brain cells, creating two distinct populations: some retaining the ITSN1 variant and others engineered to be without it. This arduous process, taking roughly 18 months, provides a powerful in vitro model to study the direct effects of the mutation on human brain cell function and development.

Complementing the cellular research, the lab is also utilizing mouse models to investigate how the ITSN1 variant impacts the brain in vivo. Researchers will spend the next few years meticulously observing these mice throughout their lifespans, assessing the variant’s effects on critical cognitive functions such as learning, memory, and executive function. "There’s very little understanding of how this gene actually can lead to either autism or Parkinson’s, and critically, why some people can be walking around with the variant and healthy while others can’t," Dhindsa explains. "We’re trying to understand all the different components of this puzzle." This multifaceted approach, spanning patient observation, cellular models, and animal studies, is essential for comprehensive understanding.

Bringing Families on the Journey: Hope Amidst Uncertainty

The groundbreaking work at the Duncan NRI holds immense promise for developing therapies and medications to help patients with rare diseases. However, as Dr. Huda Zoghbi cautions, scientific discovery is an inherently time-consuming and arduous process. For families like the Johnsons, the initial relief of finally having a genetic explanation for their children’s developmental challenges can gradually give way to the stark reality of how long and demanding the research process can be. It is therefore paramount, Zoghbi emphasizes, for Duncan NRI researchers to ensure these families feel deeply included and informed throughout the journey. "We give them hope, but we also take them along with us on the journey," she affirms. "They know we’re doing all the steps, one by one, and as fast as we can." This philosophy fosters trust and resilience, transforming patients from mere subjects into active partners in discovery.

For the Johnsons, the uncertainty surrounding ITSN1-related syndrome remains a source of both hope and apprehension. Hearing stories of older children with the variant who have experienced severe language regression is undeniably frightening. The rarity of ITSN1 also presents practical challenges, particularly in determining the most effective therapeutic interventions for Owen. The Johnsons often find themselves in the unique position of sharing new discoveries from Dhindsa’s lab with Owen’s therapists, collaboratively charting the best course of action.

Despite these challenges, the family remains profoundly optimistic. Owen and Alice recently celebrated their tenth birthday. Owen finds joy in playing tag with his siblings and has developed a passionate interest in dinosaurs, a testament to his vibrant spirit. Recent adjustments to his medication have yielded tangible improvements in his mood and concentration. Following a family move to Tomball, Owen’s new school has demonstrated exceptional support, integrating his therapists into his classroom environment throughout the school day to accommodate his learning needs. "They help me with work at school," Owen shares simply, "They help me pay attention."

The Johnsons are deeply encouraged by the ongoing breakthroughs at the Duncan NRI concerning ITSN1. While Owen will undoubtedly require support throughout his life, his parents cling to the hope that researchers will ultimately uncover therapies or medications that can prevent regression and allow him to thrive. "Of course, we would like for him to be an independent, functioning adult one day," Jennifer Johnson articulates, her voice filled with a mother’s unwavering hope. "We’re hoping (Dhindsa’s) work can yield that." The journey is long, but for Owen and countless others, the path from a puzzling diagnosis to a future defined by understanding and intervention is now within sight.